Bydureon: weekly exenatide injection launched

A prolonged-release preparation of exenatide has been launched. Bydureon is administered at a dose of 2mg once weekly by subcutaneous injection. Both Bydureon and Byetta, the existing twice-daily preparation of exenatide, are licensed for use in combination with other oral hypoglycaemics in type II diabetes.

Bydureon has been investigated in 1525 patients in 4 key studies: 2 studies comparing exenatide twice daily against once weekly administration; 1 study comparing against sitagliptin or pioglitazone; and 1 study comparing with insulin glargine. Bydureon was more effective at reducing HBA1c levels than comparator treatment in all 4 studies.

Exenatide is contraindicated in renal impairment: Bydureon in patients with creatinine clearance less than 50ml/min; Byetta may be used with caution in these patients but is contraindicated if creatinine clearance is less than 30ml/min.

View Bydureon drug record

Further Information: Lilly Eli & Co

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

A man with his sleeves rolled up sits in a bare room heating heroin in a spoon over a lighter flame.

New implant treats opioid dependence for 6 months

Patients with opioid dependence can now be given a...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...